Skip to content

Redox-responsive nanoparticles prevent post-ablation hepatocellular carcinoma recurrence by dual regulation of dendritic cells and tumor cells.

Oct 2026 · Journal of Controlled Release · pp. 115469 · 0 citations · 50 references
Medicine

Abstract

Radiofrequency ablation (RFA) is a locoregional therapy for hepatocellular carcinoma (HCC). However, the long-term efficacy for RFA is severely compromised by recurrence driven by an immunosuppressive tumor microenvironment (TME). In this study, we identify mature regulatory dendritic cells (mregDCs) as a key immune-regulatory population closely associated with this immune evasion. Following insufficient RFA (iRFA), sublethal thermal injury induces excessive reactive oxygen species (ROS) and hypoxia, which synergistically promote mregDC differentiation and upregulate PD-L1, leading to profound CD8+ T cell exhaustion. To address these challenges, we developed a redox-responsive nanoplatform for co-delivery of an ROS scavenger N-acetylcysteine (NAC) and siPD-L1. This nanoplatform effectively mitigates hypoxia and oxidative stress within the TME while reprogramming mregDCs toward an immunostimulatory phenotype via PD-L1 silencing. In both subcutaneous and orthotopic iRFA-HCC models, treatment with NPs(siPD-L1/NAC) potently activates CD8+ T cells, suppresses tumor growth, and exhibits a favorable safety profile. Our findings uncover an mregDC-mediated immune evasion mechanism underlying post-ablation recurrence and present a promising dual-regulation strategy for remodeling the post-ablation TME to potentiate durable anti-tumor immunity.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.